Tiago Marques - Pasithea Therapeutics CEO Director

KTTAW Stock  USD 0.02  0  11.11%   

Insider

Tiago Marques is CEO Director of Pasithea Therapeutics Corp
Age 47
Address 1111 Lincoln Road, Miami Beach, FL, United States, 33139
Phone702 514 4174
Webhttps://www.pasithea.com

Tiago Marques Latest Insider Activity

Tracking and analyzing the buying and selling activities of Tiago Marques against Pasithea Therapeutics stock is an integral part of due diligence when investing in Pasithea Therapeutics. Tiago Marques insider activity provides valuable insight into whether Pasithea Therapeutics is net buyers or sellers over its current business cycle. Note, Pasithea Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pasithea Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Pasithea Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6325) %, meaning that it generated substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.9 in 2024. Return On Capital Employed is likely to drop to -0.71 in 2024. At this time, Pasithea Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 464.2 K in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (8.7 B).
Pasithea Therapeutics Corp has accumulated 81.68 K in total debt. Pasithea Therapeutics has a current ratio of 36.8, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Pasithea Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

James BradySpero Therapeutics
N/A
Ian CritchleySpero Therapeutics
N/A
MBA MDSpero Therapeutics
43
Angela MDSpero Therapeutics
N/A
MBA MDMonopar Therapeutics
38
Prof MDHookipa Pharma
80
Marine PopoffHookipa Pharma
N/A
McDavid StilwellCoherus BioSciences
52
Rebecca SunshineCoherus BioSciences
61
Andreas BergthalerHookipa Pharma
N/A
Satyavrat CFASpero Therapeutics
51
Andrew MBAMonopar Therapeutics
52
Christine MBASAB Biotherapeutics
68
Lukas FlatzHookipa Pharma
N/A
MBA CMASAB Biotherapeutics
69
Reinhard KanderaHookipa Pharma
55
Karen KotzCoherus BioSciences
N/A
Susannah WalpoleSpero Therapeutics
N/A
Jason CavalierLyra Therapeutics
51
Klaus OrlingerHookipa Pharma
46
Richard HameisterCoherus BioSciences
N/A
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. Pasithea Therapeutics Corp (KTTAW) is traded on NASDAQ Exchange in USA. It is located in 1111 Lincoln Road, Miami Beach, FL, United States, 33139 and employs 8 people. Pasithea Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pasithea Therapeutics Leadership Team

Elected by the shareholders, the Pasithea Therapeutics' board of directors comprises two types of representatives: Pasithea Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pasithea. The board's role is to monitor Pasithea Therapeutics' management team and ensure that shareholders' interests are well served. Pasithea Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pasithea Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Yassine Bendiabdallah, COO Clinics
Stanley Gloss, Chief Officer
MD BA, Ex CoFounder
Tiago Marques, CEO Director
Tiago MD, CEO Director
Daniel Schneiderman, Chief Officer
Graeme Currie, Chief Officer
BA MD, Executive CoFounder

Pasithea Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pasithea Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.